SJ-3366: Sam Jin Pharmaceutical

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1146-1148

  Baba, Masanori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CYCLOPENTENYLMETHYL) 6 (3,5 DIMETHYLBENZOYL) 5 ETHYLURACIL; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; PYRIMIDINEDIONE NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATENT; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VIRUS CELL INTERACTION;

HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; PATENTS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0036707265     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. 302450 Samjin develops a new anticancer drug. Pharma Koreana 1998 8 6 62
2. 319568 Therapeutic potential of a new nonnucleoside reverse transcriptase inhibitor of HIV-1 with activity against HIV-2. Buckheit RW, White EL, Stup TL, Fliakas V, Russell JM, Lee JW, Lee SH, Oh JW, Kwon HS, Chung SG, Cho EH Antiviral Res 1999 41 2 LB2
3. 320660 International Society for Antiviral Research - 12th International Conference (Part VIII). Field H IDDB Meeting Report 1999 This paper reports on the anti-HIV-1 activity of SJ-3366 in vitro and in combination with reverse transcriptase inhibitors.
4. 341146 A highly potent NNRTI possessing potential dual activity against HIV-1 reverse transcriptase and chemokine receptor interactions. Lackman C, Watson K, Wiegand A, Turpin JA, Buckheit RW, Ching S, Cho E ICAAC 1999 39 Abs 925
5. 363900 Antiviral Research - 13th International Conference (Part V). Grierson K IDDB Meeting Report 2000
6. 365448 Antiviral Research - 13th International Conference (Part XI). Pannecouque C IDDB Meeting Report 2000 A report on the anti-HIV-2 in vitro activity of SJ-3366, discussing its possible mechanism of action.
7. 401242 SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Bucheit RW, Watson K, Fliajas Boltz V, Russell J, Loftus TL Antimicrob Agents Chemother 2001 45 2 393-400 This paper reports the antiviral activity of SJ-3366 against HIV-1, HIV-2 and resistant strains, and resistance-conferring mutations in the reverse transcriptase.
8. 405112 Antiviral Research 14th International Conference - Overnight Report (Part II). Muhsin M IDDB Meeting Report 2001 A paper describing the structure-activity relationship of SJ-3366 derivatives.
9. 405527 Antiviral Research 14th International Conference - Overnight Report (Part IV). Muhsin M IDDB Meeting Report 2001 A report on the site-directed mutagenesis of HIV-1 and susceptibility of mutant strains to SJ-3366.
10. 406732 Antiviral Research 14th International Conference (Part V) Retrovirus Infections and Antiviral Research. Este JA IDDB Meeting Report 2001 This paper describes the possible mechanisms of action of SJ-3366, mutation analysis for resistant strains, and anti-HIV activity of SJ-3366 derivatives.
11. 440080 Structure-activity relationships of SJ-3366 (2,4(1H,3H)-pyrimidinediones): Inhibition of reverse transciptase, virus attachment and HIV-1 and HIV-2 replication. Turpin JA, Watson KM, Loftus TM, Wargo H, Kwon HS, Lee SH, Lee JW, Kang DW, Chung SG, Cho EH, Buckheit RW Antiviral Res 2001 51 1 57
12. 442437 Therapeutic potential of pyrimidinedione NNRTIs: Efficacy, toxicity, mechanism of action, resistance, and combination therapy. Turpin JA, Hartman TL, Watson KM, Russell JL, Pallansch LA, Chung SG, Cho EH, Buckheit RW Jr Antiviral Res 2002 53 3 Abs 22
13. 444928 Long-term resistance selection to NNRTIs: Mutations in reverse transcriptase and other viral genes, and their contribution to resistance and viral fitness. Buckheit RW, Hartman TL, Watson KM, Russell JL, Pallansch LA, Turpin JA Antiviral Res 2002 53 3 Abs 43